Related Experiment Video

Updated: Jul 10, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K

Iridoid Glycoside Cornuside Alleviates the Symptom of Gestational Diabetes Mellitus by Suppressing Inflammation and

Xiaorong Cui1, Yani Yu1, Jia Yu1

  • 1Department of Gynecology, Zibo Central Hospital, Zibo, China.

Gynecologic and Obstetric Investigation
|November 19, 2023
PubMed
Abstract

Insights

Cornuside (CNS) improves gestational diabetes mellitus (GDM) by boosting pancreatic beta-cell function and reducing inflammation. This natural compound enhances insulin secretion and alleviates GDM symptoms in mice.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Reproductive Biology

Background:

  • Gestational diabetes mellitus (GDM) is a common pregnancy complication with significant risks.
  • Pancreatic beta-cell dysfunction and inflammation are key factors in GDM development.
  • Cornuside (CNS), an iridoid glycoside, possesses known anti-inflammatory properties.

Purpose of the Study:

  • To investigate the therapeutic effects of Cornuside (CNS) on pancreatic beta-cells and GDM.
  • To elucidate the underlying mechanisms of CNS action in GDM pathogenesis.

Main Methods:

  • MIN6 beta-cell line treated with varying CNS concentrations to assess insulin production and secretion.
  • Analysis of key gene expression (Pdx1, Rac1, Piezo, NeuroD1) and cell proliferation in treated MIN6 cells.
  • Administration of CNS to a mouse model of GDM to evaluate GDM symptom amelioration, inflammatory marker levels (IL-6, TNF-α), and NF-κB activation.

Main Results:

  • CNS significantly promoted MIN6 cell proliferation and enhanced insulin content and secretion.
  • CNS treatment upregulated the expression of Pdx1, Rac1, Piezo, and NeuroD1 in beta-cells.
  • CNS administration alleviated GDM symptoms in mice, reducing serum IL-6 and TNF-α levels and suppressing placental NF-κB activation.

Conclusions:

  • Cornuside (CNS) demonstrates therapeutic potential for GDM by improving beta-cell function.
  • CNS ameliorates GDM by mitigating inflammation and enhancing pancreatic beta-cell activity.
Keywords:
CornusideGestational diabetes mellitusInflammationβ-Cell

More Related Videos

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.5K
Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model09:44

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

3.0K

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
182
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
950
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
210
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
331
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190